Home
Resources
Publications
The Efficacy of Oral Acyclovir During Early Course of Pityriasis Rosea: A Systematic Review and Meta-Analysis

The Efficacy of Oral Acyclovir During Early Course of Pityriasis Rosea: A Systematic Review and Meta-Analysis

Hua-Ching Chang, Chih-Wei Sung, Ming-Hsiu Lin

J Dermatolog Treat. 2019 May;30(3):288-293.

PMID: 30109959

Abstract:

Background:
Acyclovir has been reported as a potential therapy for pityriasis rosea (PR) in several clinical trials on the basis of evidence of the involvement of human herpes viruses 6 and 7.
Objective:
We evaluated the efficacy of acyclovir for abating PR skin lesions within a fixed period.
Methods:
We searched 4 databases for clinical trials that used oral acyclovir to treat PR and performed systematic review and meta-analysis to determine oral acyclovir's effect on skin lesions on the 14th day after commencing treatment.
Results:
Five clinical trials including four randomized controlled trials were identified that compared the effects of oral acyclovir (n = 133) and nonacyclovir (n = 140) in patients with PR. Oral acyclovir significantly reduced erythema (odds ratio [OR] 11.30; 95% CI = 5.70-22.41; p < .01) and limited lesion formation (OR 8.67; 95% CI = 3.29-22.81; p < .01) compared with nonacyclovir treatment on the 14th day. These results were in agreement with the results of subgroup analysis of only high-dose oral acyclovir treatment and randomized controlled trials.
Conclusion:
Oral acyclovir may be a relatively safe and effective treatment in the early course of PR, and patients with PR may achieve faster symptoms control with acyclovir.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP59277893-B	Acyclovir		59277-89-3	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: